相关实验视频

Updated: Jan 13, 2026

A Multimodal Imaging Framework to Advance Phenotyping of Living Label-free Breast Cancer Cells

A Multimodal Imaging Framework to Advance Phenotyping of Living Label-free Breast Cancer Cells

Published on: August 22, 2025

多中心和多焦点乳腺瘤-叙事文献综述

Mircea-Octavian Poenaru^1,2, Mihaela Amza^1,2, Cristian-Valentin Toma^3,4

¹Department of Obstetrics and Gynecology, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.

|October 29, 2025

概括

多焦点和多中心乳腺癌 (MF/MC) 是常见的,可以通过乳腺保护疗法 (BCT) 治疗. 现代管理确保了早期MF/MC疾病的生存率超过90%.

科学领域:

在瘤学瘤学.
乳腺癌研究研究乳腺癌研究
手术瘤学手术瘤学

背景情况:

多焦点 (MF) 和多中心 (MC) 乳腺癌涉及一个乳房内的多个瘤焦点,这给诊断和治疗带来了挑战.
从历史上看,MF/MC乳腺癌通常用乳房切除术治疗,但进步导致重新考虑乳房保护疗法 (BCT).

研究的目的:

审查MF/MC乳腺癌的流行病学,病理学,成像,治疗和预后.
评估乳腺保护疗法 (BCT) 在管理多发性/多发性乳腺癌中的当前作用.

主要方法:

使用PubMed,科学网和Scopus进行了叙事文献审查.
分析包括在过去10-15年内发表的55多项相关研究,重点是系统性审查,元分析和大型队列.

主要成果:

乳腺癌的MF/MC发生在10-24%的病例中,MRI增加了检测率.
MF/MC与叶片组织学,年龄较小,结节阳性率较高 (高达45%) 相关.
当代数据显示,在适当的多式疗法下,MF/MC和单焦瘤之间没有显著的生存差异,早期疾病的生存率超过90%.

结论:

多发性乳腺癌/多发性乳腺癌是生物多样性的,需要精确的诊断和量身定制的治疗.
多学科管理,包括先进的成像,完整的切除和全身疗法至关重要.
乳腺保护越来越多地被接受为选择的MF/MC乳腺癌患者.

关键词:

乳腺保护手术是什么?多中心乳腺癌多中心乳腺癌多焦点乳腺癌是一种多焦点乳腺癌.多重的两侧乳腺瘤.预后预后预后

更多相关视频

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Optimization of Breast Biopsy and Mastectomy Sample Collection Procedures for Biobanking, Personalized Medicine, and Research Applications

Optimization of Breast Biopsy and Mastectomy Sample Collection Procedures for Biobanking, Personalized Medicine, and Research Applications

Published on: September 2, 2025

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...